Skip to main content
Top
Published in: International Urology and Nephrology 6/2016

01-06-2016 | Urology - Original Paper

Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer

Authors: Chia-En Li, Chia-Shen Chien, Yao-Chi Chuang, Ye-In Chang, Hsiu-Pei Tang, Chih-Hsiung Kang

Published in: International Urology and Nephrology | Issue 6/2016

Login to get access

Abstract

Purpose

To evaluate the impact of chronic kidney disease (CKD) on oncologic outcomes among non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder cancer.

Methods

We followed up the medical data of 158 newly diagnosed NMIBC patients enrolled in this study for more than 4 years. The ten putative risk factors included patient age, gender, white blood cells, neutrophil to lymphocyte ratio, tumor count, size, grade, stage, CKD (estimated glomerular filtration rate, eGFR < 60) and histological differentiation.

Results

Total recurrent bladder and upper urinary tract (UUT) tumors were observed in 51 patients (32 %) and 5 patients (3 %), respectively. Cancer progression to the high pT(≥pT2) stage was found in 9 patients (6 %). Cancer-specific and overall survival rates were 91 % (144/158 patients) and 78 % (123/158 patients), respectively. In univariate analysis, significant predictive determinants were tumor count, size, grade, stage, CKD and squamous differentiation for bladder tumor recurrence; CKD and squamous differentiation for UUT tumor recurrence; and tumor count, grade, stage and CKD for cancer progression. On the other hand, old age (>70 years), high grade, T1 stage, and CKD were poor prognostic factors for overall survival. In multivariate analysis, CKD was an independent risk factor for bladder/UUT tumor recurrences and the overall survival rate.

Conclusions

NMIBC patients with CKD had worse prognosis and higher tumor recurrence and progression rates than other patients. These patients should be intensively monitored at upper and lower urinary tracts and be aggressively treated for comorbidities of CKD.
Literature
1.
go back to reference Sternberg CN (2006) Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 24:3819–3820CrossRefPubMed Sternberg CN (2006) Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 24:3819–3820CrossRefPubMed
3.
go back to reference Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653CrossRefPubMed Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653CrossRefPubMed
4.
go back to reference Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477CrossRefPubMed Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477CrossRefPubMed
5.
go back to reference Antunes AA, Nesrallah LJ, Dall’Oglio MF et al (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33:339–345CrossRefPubMed Antunes AA, Nesrallah LJ, Dall’Oglio MF et al (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33:339–345CrossRefPubMed
6.
go back to reference Mano R, Baniel J, Shoshany O et al (2015) Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 33:67CrossRefPubMed Mano R, Baniel J, Shoshany O et al (2015) Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 33:67CrossRefPubMed
9.
go back to reference Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:124CrossRef Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:124CrossRef
10.
go back to reference Huang Z, Xu R, Lv C et al (2014) A chronic obstructive pulmonary disease negatively influences the prognosis of patients with bladder urothelial carcinoma via hypoxia inducible factor-1α. Int J Clin Exp Med 7:3344–3353PubMedPubMedCentral Huang Z, Xu R, Lv C et al (2014) A chronic obstructive pulmonary disease negatively influences the prognosis of patients with bladder urothelial carcinoma via hypoxia inducible factor-1α. Int J Clin Exp Med 7:3344–3353PubMedPubMedCentral
11.
go back to reference Rausch S, Hennenlotter J, Todenhofer T et al (2014) Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression—introducing a novel prognostic model for bladder cancer recurrence. Urol Oncol 32:1178–1183CrossRefPubMed Rausch S, Hennenlotter J, Todenhofer T et al (2014) Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression—introducing a novel prognostic model for bladder cancer recurrence. Urol Oncol 32:1178–1183CrossRefPubMed
12.
go back to reference van der Heijden AG, Witjes JA (2009) Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol 8:556–562CrossRef van der Heijden AG, Witjes JA (2009) Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol 8:556–562CrossRef
13.
go back to reference Gulpinar O, Halilioglu AH, Gokce MI et al (2012) The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette–guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study. Int Braz J Urol 38:474–479PubMed Gulpinar O, Halilioglu AH, Gokce MI et al (2012) The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette–guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study. Int Braz J Urol 38:474–479PubMed
14.
go back to reference Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guerin: external validation of the EORTC risk tables. Eur Urol 60:423–430CrossRefPubMed Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guerin: external validation of the EORTC risk tables. Eur Urol 60:423–430CrossRefPubMed
15.
go back to reference Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72:247–259CrossRefPubMed Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72:247–259CrossRefPubMed
16.
go back to reference Weng PH, Hung KY, Huang HL et al (2011) Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 6:1121–1128CrossRefPubMedPubMedCentral Weng PH, Hung KY, Huang HL et al (2011) Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 6:1121–1128CrossRefPubMedPubMedCentral
17.
go back to reference Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905–913CrossRefPubMed Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905–913CrossRefPubMed
18.
go back to reference Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116:2967–2973CrossRefPubMed Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116:2967–2973CrossRefPubMed
19.
go back to reference Grollman AP (2013) Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ Mol Mutagen 54:1–7CrossRefPubMed Grollman AP (2013) Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ Mol Mutagen 54:1–7CrossRefPubMed
20.
go back to reference Kang CH, Yu TJ, Hsieh HH et al (2003) The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 98:1620–1626CrossRefPubMed Kang CH, Yu TJ, Hsieh HH et al (2003) The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 98:1620–1626CrossRefPubMed
21.
go back to reference Kang CH, Chen CH, Chiang PH (2010) Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up. Jpn J Clin Oncol 40:241–246CrossRefPubMed Kang CH, Chen CH, Chiang PH (2010) Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up. Jpn J Clin Oncol 40:241–246CrossRefPubMed
23.
go back to reference Chang CH, Yang CM, Yang AH (2007) Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 109:1487–1492CrossRefPubMed Chang CH, Yang CM, Yang AH (2007) Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 109:1487–1492CrossRefPubMed
24.
go back to reference Neves TR, Soares MJ, Monteiro PG (2011) Basaloid squamous cell carcinoma in the urinary bladder with small-cell carcinoma. J Clin Oncol 29:e440-2–e442CrossRefPubMed Neves TR, Soares MJ, Monteiro PG (2011) Basaloid squamous cell carcinoma in the urinary bladder with small-cell carcinoma. J Clin Oncol 29:e440-2–e442CrossRefPubMed
25.
go back to reference Wang LJ, Lee SY, Teh BT et al (2014) Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge. Biomed Res Int 2014:989458PubMedPubMedCentral Wang LJ, Lee SY, Teh BT et al (2014) Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge. Biomed Res Int 2014:989458PubMedPubMedCentral
26.
go back to reference Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus calmette–guerin. Eur Urol 62:118–125CrossRefPubMed Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus calmette–guerin. Eur Urol 62:118–125CrossRefPubMed
27.
go back to reference Onishi T, Sasaki T, Hoshina A, Yabana T (2011) Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res 31:1471–1474PubMed Onishi T, Sasaki T, Hoshina A, Yabana T (2011) Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res 31:1471–1474PubMed
28.
go back to reference Kobayashi H, Kikuchi E, Mikami S et al (2014) Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression. BMC Urol 14:5CrossRefPubMedPubMedCentral Kobayashi H, Kikuchi E, Mikami S et al (2014) Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression. BMC Urol 14:5CrossRefPubMedPubMedCentral
Metadata
Title
Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer
Authors
Chia-En Li
Chia-Shen Chien
Yao-Chi Chuang
Ye-In Chang
Hsiu-Pei Tang
Chih-Hsiung Kang
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1264-5

Other articles of this Issue 6/2016

International Urology and Nephrology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine